What We're Reading: Page 82
Industry reads hand-picked by our editors
Dec 04, 2023
-
The Wall Street Journal
The Opioid Victims Who Won’t Sign Off on Purdue’s $6 Billion Settlement
-
FirstWord Pharma
Roche hits snag in clinical programme for MS hopeful fenebrutinib
-
Reuters
AstraZeneca, AI biologics firm Absci tie up on cancer drug
-
CNN
Biden’s prescription for 2024 turnaround will include major health care focus
Dec 01, 2023
-
Reuters
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
-
MIT Technology Review
How will the Broad Institute use its CRISPR patent now that the first cure is here?
-
The Hill
Texas AG Paxton suing Pfizer for attempted censorship, ‘misrepresenting’ COVID-19 vaccination
-
The Wall Street Journal
The Fight Against Frown Lines Has Never Been More Complicated
Nov 30, 2023
Nov 29, 2023
-
Bloomberg
Bayer M&A Simulation Game Casts Doubt on Any Quick Fixes
-
San Francisco Business Times
Personalized approach to Alzheimer’s Disease draws documentary, criticism
-
ApexOnco
Argenx’s efforts to Advance fall flat
Nov 28, 2023
-
LifeSciVC
Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market
-
Reuters
Lilly’s Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
-
Axios
Biden looks to boost domestic drug manufacturing amid shortages
-
USA Today
Medical treatment designed for one patient may be the future for many
Nov 27, 2023
-
Stat
As biotech industry slumps, bioscience job market is upside down
-
Axios
The big question about obesity drugs: Can people ever stop taking them?
-
KFF Health News
Many Autoimmune Disease Patients Struggle With Diagnosis, Costs, Inattentive Care
-
Fierce Biotech
CRISPR Therapeutics laid off staff a week after positive adcomm
Nov 22, 2023
-
Fierce Pharma
CEOs of J&J, Merck, BMS called to testify on drug prices
-
Bloomberg
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
-
Stat
Prominent pharmaceutical industry ally Anna Eshoo to retire
-
The Wall Street Journal
Senators Call for Investigation of Health Insurers’ Role in Driving Up Drug Costs
Previous
